OakChart

Nutriband Inc

NTRBHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

5.94+0.18 (3.12%)
2026-11-12 05:01 CET
Market cap
72.20 USD m
Revenue, TTM
1.62 USD m
Net income, TTM
-6.96 USD m
Free cash flow, TTM
-3.63 USD m
EPS diluted, TTM
-0.58
P/E
-
Compare

Price

NTRB against its 20, 50 and 200-day averages
2050200
4.006.008.00205K410KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NTRBclose 5.9420-day 6.0450-day 6.57200-day 4.425.9452w high52w low

35.3% under the 52-week high of 9.19 on 25 Sep 2026. 52-week low 2.80 on 4 Aug 2026. Last 15 sessions, 26.0% high to low

Volume 0.11× normal · the line is the 50-bar volume average

Profile

NTRB
52-week range, 49% of the way up
2.809.19

Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. It operates through the Pocono Pharmaceuticals and 4P Therapeutics segments. The Pocono Pharmaceuticals segment relates to a coated products manufacturing entity. The 4P Therapeutics segment performs contract research and development services. The company was founded by Gareth R. Sheridan and Serguei Melnik in 2012 and is headquartered in Orlando, FL.

IPONov 30, 2017
Beta2.19
ATR, 14d0.51
Rel volume0.11
Short float2.64%
Insider own56.82%
Inst own3.24%

Snapshot

6 groups

Valuation

Index-
Market Cap72.21M
Enterprise Value69.01M
Income-6.96M
Sales1.62M
Book/sh0.44
Cash/sh0.28
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPONov 30, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S44.57
P/B13.56
P/C21.11
P/FCF-
EV/EBITDA-
EV/Sales42.60
Quick Ratio4.02
Current Ratio4.21
Debt/Eq0.04
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.58
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-69.50% -42.74%
Sales past 3/5Y-0.69% 16.63%
EPS Y/Y TTM79.94%
Sales Y/Y TTM-37.25%
EPS Q/Q96.59%
Sales Q/Q-29.71%
EarningsMay 01
EPS/Sales Surpr.0.00% 0.00%

Ownership

Insider Own56.82%
Insider Trans0.00%
Inst Own3.24%
Inst Trans-2.25%
ROA-84.55%
ROE-100.75%
ROIC-129.28%
Gross Margin31.06%
Oper. Margin-435.58%
Profit Margin-430.43%
SMA20-1.72%
SMA50-9.58%
SMA20034.37%
Trades-

Technical

Shs Outstand12.16M
Shs Float5.25M
Short Float2.64%
Short Ratio2.00
Short Interest0.14M
52W High9.19 -35.33%
52W Low2.80 112.14%
Volatility8.59% 7.19%
ATR (14)0.51
RSI (14)47.16
Beta2.19
Rel Volume0.11
Avg Volume69.35K
Volume7,589

Performance

Perf Week-2.30%
Perf Month-8.90%
Perf Quarter86.21%
Perf Half Y69.71%
Perf YTD30.84%
Perf Year-2.46%
Perf 3Y166.37%
Perf 5Y15.89%
Perf 10Y-
Recom1.00
Target Price15.00
Prev Close5.76
Price5.94
Change %3.12%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Jan 22, 2025InitiatedNNoble Capital MarketsOutperform$13+118.9%

Peers

Mkt cap
TickerCompanyMkt cap
ENSCEnsysce Biosciences Inc7.00M
HRTXHeron Therapeutics Inc68.36M
VANIVivani Medical Inc101.93M
RANIRani Therapeutics Holdings Inc79.18M
CINGCingulate Inc67.47M
LPCNLipocine Inc17.61M
PLRZPolyrizon Ltd26.14M
LEXXLexaria Bioscience Corp9.78M
AEONAEON Biopharma Inc10.12M
CTXRCitius Pharmaceuticals Inc13.20M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274 (GlobeNewswire) +11.45%
  • Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology (GlobeNewswire) -10.44%
  • Nutriband Marks Five Years on Nasdaq - CEO Letter to Shareholders (GlobeNewswire)
  • Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis (GlobeNewswire)
  • Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board (GlobeNewswire) -11.01%
  • Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing (GlobeNewswire) -13.00%
  • Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit (GlobeNewswire)
  • Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch (GlobeNewswire)
  • Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight (GlobeNewswire)
  • Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference (GlobeNewswire)
  • Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast (GlobeNewswire)
  • Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch (GlobeNewswire) -10.36%
  • Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica (GlobeNewswire)
  • Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2025Q42026-05-01-1.890-1.890-0.0800.770.771
2025Q32025-12-01-2.130-2.130-0.3210.680.681
2025Q22025-10-01-2.120-2.120-0.1200.620.621
2025Q12025-07-02-0.120-0.120-0.1250.670.671
2024Q42025-05-02-0.500-0.500-0.4980.640.641
2024Q32024-12-02-0.120--0.1230.65--
2022Q22022-09-28-0.120-0.120-0.1060.460.461
2022Q12022-05-31-0.080-0.060-0.0750.480.502
2021Q42022-04-29-0.437-0.090-0.4120.490.332
2021Q32022-04-08-0.231--0.2330.28-2
2021Q22021-12-14-0.0690.009-0.0700.210.711
2021Q12021-09-03-0.0430.000-0.0430.430.511
2020Q42021-06-14-0.2910.000-0.3090.350.47-
2020Q32020-12-15-0.009-0.034-0.0070.390.24-
2020Q22020-09-11-0.034-0.060-0.0350.080.101
2020Q12020-06-04-0.283-0.111-0.0650.120.04-

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-0.549-0.411-0.5340.250.76
2019FY-0.429-0.291-0.4300.370.45
2020FY-0.437-0.103-0.4360.941.06
2021FY-0.925--0.8031.42-
2024FY-0.990-0.990-2.302.30
2025FY-6.200-6.200-2.732.73
2026FY-1.570---
2027FY-3.660--180.41

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026FYE2025-09-011001.571.571.57
2026FYE2025-07-111101.571.571.57
2026FYE2025-07-101101.571.571.57
2026FYE2025-07-091101.571.571.57
2026FYE2025-07-081101.571.571.57
2026FYE2025-07-071101.571.571.57
2026FYE2025-07-061101.571.571.57
2026FYE2025-07-051101.571.571.57
2026FYE2025-07-041101.571.571.57
2026FYE2025-07-031101.571.571.57
2026FYE2025-07-021101.571.571.57
2026FYE2025-07-011101.571.571.57
2026FYE2025-06-301101.571.571.57
2026FYE2025-06-291101.571.571.57

Estimate history

EPS, annual-0.477-0.534-0.43-0.436-0.803-0.53-0.69-0.988-2.581-0.5754
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.154-0.123-0.498-0.125-2.123-0.321-0.08-0.102-0.072
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00.2450.3710.9441.4222.082.0852.142.0371.62
Period201720182019202020212022202320242025TTM
Sales, quarterly0.4430.6460.6420.6670.6220.3460.4010.4330.438
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual6.0896.3286.3487.39.157.8338.8611.07512.15612.156
Period201720182019202020212022202320242025MRQ
Shares, quarterly11.09611.10611.07511.1312.01612.15612.15612.15612.156
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1.622.042.142.092.081.420.940.370.25
Cost of Goods Sold Incl. D&A1.121.511.441.271.330.920.580.550.29
Gross Profit0.500.520.700.820.750.500.36-0.18-0.04
Selling, General and Administrative Excl. Other7.558.847.395.694.904.432.961.793.29
Research and Development1.211.893.121.960.980.41---
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-7.05-8.32-6.69-4.87-4.15-3.93-2.60-1.97-3.33
Interest Expense0.020.020.020.080.010.120.280.07-
Unusual Expense0.000.003.960.550.332.130.060.680.00
Net Income Before Taxes-6.96-8.23-10.48-5.49-4.48-6.18-2.93-2.72-3.33
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-6.96-8.23-10.48-5.49-4.48-6.18-2.93-2.72-3.33
Net Income From Continuing Operations-6.96-8.23-10.48-5.49-4.48-6.18-2.93-2.72-3.33
Net Income-6.96-30.04-10.48-5.49-4.48-6.37-2.93-2.72-3.33
EPS (Recurring)-0.57-2.58-0.73-0.64-0.50-0.62-0.43-0.36-0.53
EPS (Basic, Before Extraordinaries)-0.58-2.58-0.99-0.69-0.53-0.80-0.44-0.43-0.53
EPS (Diluted)-0.58-2.58-0.99-0.69-0.53-0.80-0.44-0.43-0.53
EBITDA-6.90-8.12-6.40-4.58-3.78-3.61-2.43-1.88-3.29
Non-Operating Income (Expense)0.100.110.190.020.000.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.412.631.540.741.021.312.000.251.76
Price To Sales Ratio21.4227.3841.109.9614.8520.89110.07192.07676.01
Gross Margin31.0625.6832.6839.2736.0835.4638.29-48.15-17.54
Operating Margin-435.58-408.41-312.67-233.63-199.45-276.33-275.08-531.35-1,358.11
Net Margin-430.43-1,475.16-489.95-263.04-215.59-448.10-310.78-734.29-1,358.11
Shares Outstanding12.1612.1611.078.867.839.157.306.356.33
Market Capitalization72.2072.2073.6616.3622.8727.4288.2259.85124.97

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.440.430.400.350.620.670.640.65
Cost of Goods Sold Incl. D&A0.260.240.330.280.470.440.370.47
Gross Profit0.180.190.070.060.150.230.270.18
Selling, General and Administrative Excl. Other1.071.451.093.942.151.642.241.61
Research and Development0.320.250.190.460.560.680.490.88
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.89-1.25-1.02-3.88-2.00-1.41-1.96-1.43
Interest Expense0.000.010.010.010.010.010.000.00
Unusual Expense0.000.000.000.000.000.003.600.00
Net Income Before Taxes-0.88-1.24-0.97-3.87-2.00-1.39-5.52-1.36
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-0.88-1.24-0.97-3.87-2.00-1.39-5.52-1.36
Net Income From Continuing Operations-0.88-1.24-0.97-3.87-2.00-1.39-5.52-1.36
Net Income-0.88-1.24-0.97-3.87-23.81-1.39-5.52-1.36
EPS (Recurring)-0.07-0.10-0.08-0.32-2.12-0.12-0.27-0.12
EPS (Basic, Before Extraordinaries)-0.07-0.10-0.08-0.32-2.12-0.12-0.50-0.12
EPS (Diluted)-0.07-0.10-0.08-0.32-2.12-0.12-0.50-0.12
EBITDA-0.86-1.22-0.99-3.84-1.95-1.36-1.89-1.35
Non-Operating Income (Expense)0.010.020.060.010.010.030.050.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.220.550.102.540.040.060.990.00
Price To Sales Ratio21.4226.0628.5935.6231.3731.9142.9133.99
Gross Margin40.7444.5317.0318.2123.8634.2142.7527.82
Operating Margin-203.57-289.42-254.78-1,121.30-321.83-211.78-305.67-220.94
Net Margin-201.26-286.56-241.59-1,118.99-3,825.92-208.09-858.75-211.00
Shares Outstanding12.1612.1612.1612.1612.0211.1311.0711.11
Market Capitalization72.2047.0658.3280.9980.4261.1373.6655.00

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments4.574.310.491.994.890.150.010.470.00
Short Term Receivables0.120.070.150.110.070.110.010.010.00
Inventories0.120.210.170.230.130.050.000.000.00
Other Current Assets0.180.200.210.370.370.000.020.100.16
Total Current Assets4.994.791.022.695.470.310.040.590.16
Net Property, Plant & Equipment0.640.700.810.961.001.080.120.150.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets1.921.985.695.806.288.542.032.070.00
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets7.557.477.529.4612.749.932.202.810.16
Short Term Debt Incl. Current Port. of LT Debt0.160.130.160.050.031.540.290.040.03
Accounts Payable0.500.700.680.530.640.940.770.290.00
Other Current Liabilities0.120.160.160.160.110.090.960.070.01
Total Current Liabilities0.780.981.000.750.782.572.020.400.04
Long Term Debt0.080.060.080.130.100.250.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities0.871.041.080.880.882.822.020.400.04
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity6.686.436.448.5711.867.110.182.400.12
Total Shareholders Equity6.686.436.448.5711.867.110.182.400.12
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity6.686.436.448.5711.867.110.182.400.12
Total Liabilities & Stockholders Equity7.557.477.529.4612.749.932.202.810.16
Book Value Per Share0.550.580.731.091.300.970.030.380.02
Tangible Book Value Per Share0.390.400.080.350.61-0.20-0.290.050.02
Full-Time Employees----1355710
Price to Book Ratio13.566.562.872.672.3112.16341.1251.97343.72
Return on Assets-109.60-139.89-64.63-40.40-54.49-48.38-108.75-224.14-2,637.32
Return on Equity-125.56-162.94-73.08-43.89-65.11-80.49-210.98-263.74-3,695.20
Return on Invested Capital-121.67-161.59-84.16-51.49-51.64-39.85-1,551.38-138.54-2,198.99
Quick Ratio6.214.660.853.296.840.100.021.473.71
Current Ratio6.364.881.023.607.010.120.021.473.80

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-6.96-8.23-10.48-5.49-4.48-6.18-2.93-2.72-3.33
Depreciation0.150.190.290.290.370.320.170.090.04
Other Funds (Non Cash)3.442.775.541.451.353.592.361.021.79
Funds from Operations-3.37-5.26-4.66-3.75-2.77-2.27-0.41-1.61-1.51
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.260.130.030.22-0.22-0.540.110.710.40
Cash from Operating Activities-3.63-5.13-4.63-3.53-2.99-2.81-0.30-0.89-1.11
Capital Expenditures0.00-0.01-0.09-0.05-0.08-0.080.000.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-0.40
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.070.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.00-0.01-0.09-0.05-0.08-0.080.070.00-0.40
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.075.42-0.150.000.189.260.580.252.00
Repurchase of Common Pref Stock-0.000.00-0.150.00-0.12-0.100.000.000.00
Sale of Common Pref Stock0.075.420.000.000.309.360.580.252.00
Proceedsfrom Stock Options0.000.000.000.000.006.420.060.251.50
Issuance or Reduction of Debt, Net-0.02-0.028.692.09-0.02-1.63-0.160.17-0.02
Change in Long Term Debt-0.02-0.028.692.09-0.02-1.630.180.000.00
Issuance of Long Term Debt0.000.008.712.110.000.000.190.000.00
Reduction of Long Term Debt-0.02-0.02-0.02-0.02-0.02-1.63-0.020.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00-0.040.010.00
Other Financing Activities Uses0.000.000.000.000.000.00-0.05-0.030.00
Cash from Financing Activities0.065.408.542.090.167.630.370.431.98
Exchange Rate Effect----0.000.000.00-0.000.00
Net Change in Cash-3.570.263.82-1.49-2.914.740.14-0.460.47
Free Cash Flow-3.63-5.14-4.72-3.58-3.07-2.89-0.30-0.89-1.11
Preferred Dividends (Cash Flow)--0.000.000.00-0.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments3.424.014.575.317.002.96
Short Term Receivables0.020.000.120.150.160.09
Inventories0.170.120.120.140.140.22
Other Current Assets0.200.250.180.220.230.16
Total Current Assets3.824.384.995.827.523.43
Net Property, Plant & Equipment0.580.610.640.670.710.76
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets1.891.901.921.941.951.97
Other Assets0.000.000.000.000.000.00
Total Assets6.296.897.558.4210.186.15
Short Term Debt Incl. Current Port. of LT Debt0.160.160.160.160.160.16
Accounts Payable0.640.640.500.611.390.72
Other Current Liabilities0.100.030.120.010.020.04
Total Current Liabilities0.910.830.780.771.570.93
Long Term Debt0.060.070.080.100.110.12
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.960.900.870.871.681.05
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity5.335.996.687.558.495.10
Total Shareholders Equity5.335.996.687.558.495.10
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity5.335.996.687.558.495.10
Total Liabilities & Stockholders Equity6.296.897.558.4210.186.15
Book Value Per Share0.440.490.550.620.710.46
Tangible Book Value Per Share0.280.340.390.460.540.28
Price to Book Ratio13.567.047.729.5215.729.48
Return on Assets-84.55-123.93-109.60-121.91-86.25-93.62
Return on Equity-100.75-145.72-125.56-136.08-98.00-108.02
Return on Invested Capital-16.35-20.49-14.31-50.64-23.25-26.57
Quick Ratio4.025.116.217.354.703.47
Current Ratio4.215.266.367.534.783.71

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-0.88-1.24-0.97-3.87-2.00-1.39
Depreciation0.030.030.040.040.060.06
Other Funds (Non Cash)0.230.560.112.540.050.07
Funds from Operations-0.62-0.65-0.82-1.28-1.89-1.26
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.030.080.09-0.470.58-0.08
Cash from Operating Activities-0.58-0.56-0.73-1.75-1.31-1.34
Capital Expenditures0.000.000.000.000.00-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.00-0.01
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-----0.00
Change in Capital Stock-0.000.000.000.075.350.00
Repurchase of Common Pref Stock-0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.075.350.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.00-0.01-0.01-0.01-0.01-0.01
Change in Long Term Debt0.00-0.01-0.01-0.01-0.01-0.01
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.00-0.01-0.01-0.01-0.01-0.01
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.00-0.01-0.010.075.34-0.01
Net Change in Cash-0.58-0.57-0.74-1.684.03-1.35
Free Cash Flow-0.58-0.56-0.73-1.75-1.31-1.34

Revenue breakdown

Non-US2025: 7.63K
Sale Of Goods2024: 2.14M
United States2025: 2.03M
United States2024: 2.14M 2025: 2.04M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.64%0.1M5.3M68.06K
2026-10-153.01%0.2M5.3M64.88K
2026-09-302.92%0.2M5.3M60.39K
2026-09-153.39%0.2M5.3M28.84K
2026-08-313.29%0.2M5.3M17.00K
2026-08-143.24%0.2M5.3M11.07K
2026-07-313.22%0.2M5.3M11.95K
2026-07-152.99%0.2M5.3M11.62K
2026-06-302.92%0.2M5.3M10.39K
2026-06-153.40%0.2M5.3M10.19K
2026-05-293.28%0.2M5.3M11.14K
2026-05-153.53%0.2M5.3M10.83K
2026-04-303.89%0.2M5.3M10.82K
2026-04-154.30%0.2M4.9M12.69K
2026-03-314.41%0.2M4.9M14.53K
2026-03-134.04%0.2M4.9M30.11K
2026-02-274.12%0.2M4.9M31.07K
2026-02-133.93%0.2M4.9M33.26K
2026-01-303.87%0.2M4.9M35.15K
2026-01-154.13%0.2M4.9M41.92K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-3025-NSESEC
2026-09-238-KCurrent report2026-09-21SEC
2026-09-15SCHEDULE 13D/ASEC
2026-09-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-07-31SEC
2026-06-228-KCurrent report2026-06-01SEC
2026-06-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-04-30SEC
2026-05-1810-K/A2026-01-31SEC
2026-04-2910-KAnnual report pursuant to Section 13 or 15(d)2026-01-31SEC
2026-04-078-KCurrent report2026-03-30SEC
2026-02-138-KCurrent report2026-02-13SEC
2026-02-13424B3SEC
2026-02-038-KCurrent report2026-01-24SEC
2025-12-308-KCurrent report2025-12-30SEC
2025-12-19DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-01-24SEC
2025-12-1110-QQuarterly report pursuant to Section 13 or 15(d)2025-10-31SEC
2025-11-255Annual statement of changes in beneficial ownership of securities2025-01-31SEC
2025-10-288-KCurrent report2025-10-28SEC
2025-10-215Annual statement of changes in beneficial ownership of securities2025-01-31SEC
2025-10-20424B3SEC
2025-09-0910-QQuarterly report pursuant to Section 13 or 15(d)2025-07-31SEC
2025-09-038-KCurrent report2025-02-01SEC
2025-08-078-KCurrent report2025-08-05SEC
2025-07-168-KCurrent report2025-07-14SEC
2025-07-08424B4SEC
2025-07-03EFFECTEffectiveness filing by commission orderSEC
2025-07-03POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2025-06-23POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2025-05-3010-QQuarterly report pursuant to Section 13 or 15(d)2025-04-30SEC
2025-05-1310-K/A2025-01-31SEC
2025-04-2810-KAnnual report pursuant to Section 13 or 15(d)2025-01-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC1.44%
GEODE CAPITAL MANAGEMENT, LLC0.54%
VANGUARD FIDUCIARY TRUST CO0.21%
STATE STREET CORP0.21%
BFC Planning, Inc.0.16%
CITADEL ADVISORS LLC0.16%
UBS Group AG0.14%
NORTHERN TRUST CORP0.10%
Haven Private, LLC0.09%
BlackRock, Inc.0.09%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.25%
Fidelity Extended Market Index Fund0.21%
VANGUARD EXTENDED MARKET INDEX FUND0.11%
iShares Micro-Cap ETF0.08%
Fidelity Total Market Index Fund0.08%
Fidelity Nasdaq Composite Index Fund0.07%
Fidelity Series Total Market Index Fund0.06%
1290 VT Micro Cap Portfolio0.01%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. NTRB. Cached 15 minutes.

Some panels did not load: insider.